End point (outcome) | Number of trials (number of patients) | Number of events in each group (%) | Resultsa | Absolute effect per 1,000 treated patientsb | Quality of evidence |
---|---|---|---|---|---|
Hospital mortality | 3 (431) | Intervention: 76/223 (34%) | RR, 0.72 (CI, 0.58 to 0.91); P = 0.005; I2 = 0 | 132 fewer per 1,000 (from 42 fewer to 198 fewer) | Moderatec |
 |  | Control: 98/208 (47%) |  |  |  |
ICU mortality | 3 (431) | Intervention: 70/223 (31.4%) | RR, 0.70 (CI, 0.55 to 0.89); P = 0.004; I2 = 0 | 134 fewer per 1,000 (from 49 fewer to 201 fewer) | Moderatec |
 |  | Control: 93/208 (44.7%) |  |  |  |
Mortality at 28 days | 3 (431) | Intervention: 57/223 (25.6%) | RR, 0.66 (CI, 0.50 to 0.87); P = 0.003; I2 = 0 | 132 fewer per 1,000 (from 51 fewer to 195 fewer) | Moderatec |
 |  | Control: 81/208 (39%) |  |  |  |
Days free of mechanical ventilation at 28 days | 3 (431) | n/a | MD, 1.91 (CI, 0.28 to 3.55); P = 0.02; I2 = 0 | n/a | Moderatec |
Duration of mechanical ventilation | 3 (431) | n/a | MD, 1.21 (CI, 4.23 to 1.81); P = 0.43; I2 = 0 | n/a | Moderatec |
Barotrauma | 3 (431) | Intervention: 9/223 (4%) | RR, 0.43 (CI, 0.20 to 0.90); P = 0.02; I2 = 0 | 55 fewer per 1,000 (from 10 fewer to 77 fewer) | Moderatec |
 |  | Control: 20/208 (9.6%) |  |  |  |
ICU Acquired weakness | 3 (431) | Intervention: 73/223 (32.7%) | RR, 1.08 (CI, 0.83 to 1.41); P = 0.57; I2 = 0 | 24 more per 1,000 (from 51 fewer to 122 more) | Very weakcde |
 |  | Control: 62/208 (30%) |  |  |  |
ICU Length of stay | 1 (339) | n/a | MD, 1.80 (CI, 5.93 to 2.33); P = 0.39 | n/a | n/a |